

CDDF Multi-stakeholder Workshop

New modalities in cancer drug development

31 March - 1 April 2025
Brussels, BE

(DRAFT PROGRAMME)

Meeting Secretariat

Giorgia Campagnano - giorgia@cddf.org

EVENT OUTLINE:**LEARNING OBJECTIVES:****PROGRAMME COMMITTEE**

Programme chair: Stefan Symeonides (CDDF, UK)

Programme chair: Christian Schneider (CDDF, DE)

Hemal Morjaria (Johnson & Johnson, UK)

Sacha Wissink (MSD, NL)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs, and patient advocates

EXPECTED NUMBER OF PARTICIPANTS:

+/- 60 onsite participants/ +/- 150 online participants

MEETING DATE:

31 March - 1 April 2025

MEETING VENUE:

Brussels Marriott Hôtel Grand Place

DRAFT PROGRAMME

DAY 1 - 31 MARCH 2025

12:00-12:50: Lunch
12:50-13:00: Welcome Note

Session 1: What is new in Oncology?

Session chairs:

13:00-13:15 Variants on ADCs , novel payloads (cytokines)
13:15-13:30 Bispecific and their variants; T cell engagers
13:30-13:45 Undruggable
13:45-14:25 Panel discussion
Guest panelists:
- Patient perspective
- Regulatory perspective
14:25-14:55 Coffee break

Session 2: Radiopharmaceuticals

Session chairs:

14:55-15:00 Session opening
15:00-15:15 Science biology talk on what is out there, what is coming, how they work (Basic principles of radiopharmaceuticals), setting the scene; theranostics
15:15-15:30 Regulatory Requirements
15:30-15:45 FDA perspective
15:45-16:25 Panel discussion
Guest panelist:
- Patient perspective
- Medical oncologist perspective

Session 3: Personalized medicine in Oncology

Session chairs:

16:25-16:30 Session opening
16:30-16:45 Short overview, including vector technology, types of antigens
16:45-17:00 How to choose antigen, AI and epitope selection
17:00-17:15 Regulatory perspective, how to treat a personalised vaccine as an IMP
17:15-17:55 Panel discussion

18:10-19:10 Industry panel meeting (Internal meeting) - **TBC**
19:30-22:00 Welcome Drink & Networking Dinner

DAY 2 - 1 APRIL 2025

8:30 - 10:00 CDDF Board meeting (internal meeting) -**TBC**

Session 4: Cellular therapies

Session chairs:

10:15-10:20 Session opening

Session chairs

10:20-10:35 Cellular therapies and GMOs: What is out there and pipeline (ideally include oncolytics, intratumorals and microbiome therapy), Next generation CAR T cells – academic perspective

10:35-10:50 Regulations including GMOs (EMA perspective)

10:50-11:05 Delivery of them: Learnings from CAR T cells (HTA perspective)

11:05-11:45 Panel discussion

Guest panelist:

- Patient perspective

Session 5: Discussion session on common challenges

Session chairs: Programme chairs

Panel discussion about how we can deliver these new therapies to patients. Trial regulations, licensing, requirements, HTA assessment, infrastructure building

11:45-12:15 Wrap up panel discussion (all stakeholders)

12:15-12:25 Farewell message

Programme chair

12:30-13:30 Sandwich lunch and departure